UTHR - UNITED THERAPEUTICS Corp
IEX Last Trade
364.09
-0.275 -0.076%
Share volume: 3,375
Last Updated: Thu 26 Dec 2024 08:29:56 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$364.36
-0.28
-0.08%
Fundamental analysis
62%
Profitability
76%
Dept financing
5%
Liquidity
70%
Performance
60%
Performance
5 Days
-0.76%
1 Month
-4.28%
3 Months
0.88%
6 Months
13.14%
1 Year
66.86%
2 Year
29.43%
Key data
Stock price
$364.09
DAY RANGE
$360.20 - $364.99
52 WEEK RANGE
$212.36 - $417.82
52 WEEK CHANGE
$64.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Martine A. Rothblatt
Region: US
Website: unither.com
Employees: 980
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: unither.com
Employees: 980
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Recent news